Sonnet Biotherapeutics Holdings Inc (SONN) - Net Assets
Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) has net assets worth $-3.05 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.06 Million) and total liabilities ($5.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SONN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.05 Million |
| % of Total Assets | -148.22% |
| Annual Growth Rate | 6.49% |
| 5-Year Change | -51.54% |
| 10-Year Change | -22.74% |
| Growth Volatility | 2924.73 |
Sonnet Biotherapeutics Holdings Inc - Net Assets Trend (2007–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's net assets have evolved over time, based on quarterly financial data. Also explore Sonnet Biotherapeutics Holdings Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Sonnet Biotherapeutics Holdings Inc (2007–2025)
The table below shows the annual net assets of Sonnet Biotherapeutics Holdings Inc from 2007 to 2025. For live valuation and market cap data, see market cap of Sonnet Biotherapeutics Holdings Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $10.79 Million | +2320.86% |
| 2024-09-30 | $-485.74K | -114.95% |
| 2023-09-30 | $-225.98K | +91.10% |
| 2022-09-30 | $-2.54 Million | -111.40% |
| 2021-09-30 | $22.26 Million | +637.10% |
| 2020-09-30 | $3.02 Million | +206.13% |
| 2019-09-30 | $-2.85 Million | -134.46% |
| 2018-12-31 | $8.26 Million | -28.13% |
| 2017-09-30 | $11.49 Million | -17.71% |
| 2016-09-30 | $13.96 Million | -35.83% |
| 2015-12-31 | $21.76 Million | +45.31% |
| 2015-09-30 | $14.97 Million | +33.22% |
| 2013-12-31 | $11.24 Million | 0.00% |
| 2013-09-30 | $11.24 Million | +584.78% |
| 2012-09-30 | $1.64 Million | -98.01% |
| 2011-09-30 | $82.42 Million | +11379.52% |
| 2009-09-30 | $718.02K | -53.35% |
| 2008-09-30 | $1.54 Million | -55.71% |
| 2007-09-30 | $3.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sonnet Biotherapeutics Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13369247200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $708.00 | 0.01% |
| Other Components | $144.48 Million | 1339.31% |
| Total Equity | $10.79 Million | 100.00% |
Sonnet Biotherapeutics Holdings Inc Competitors by Market Cap
The table below lists competitors of Sonnet Biotherapeutics Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oncosil Medical Ltd
AU:OSL
|
$8.61 Million |
|
PEREGRINE GOLD LTD
F:9VA
|
$8.61 Million |
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
$8.61 Million |
|
GENFLOW BIOSCIENCES PLC
F:WQ5
|
$8.61 Million |
|
TIMES CHINA HLDGS HD -10
F:T2H
|
$8.60 Million |
|
Envirotech Vehicles Inc
NASDAQ:EVTV
|
$8.60 Million |
|
Allurion Technologies, Inc.
NYSE:ALUR
|
$8.60 Million |
|
Korporacja Gospodarcza efekt S.A
WAR:EFK
|
$8.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sonnet Biotherapeutics Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -485,739 to 10,787,579, a change of 11,273,318.
- Net loss of 16,112,737 reduced equity.
- Other factors increased equity by 27,386,055.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.11 Million | -149.36% |
| Other Changes | $27.39 Million | +253.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Sonnet Biotherapeutics Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-09-30 | $2316850.67 | $1.26 | x |
| 2008-09-30 | $1026090.67 | $1.26 | x |
| 2009-09-30 | $478678.67 | $1.26 | x |
| 2011-09-30 | $41212500.00 | $1.26 | x |
| 2012-09-30 | $567911.07 | $1.26 | x |
| 2013-09-30 | $1650366.23 | $1.26 | x |
| 2013-12-31 | $129183.84 | $1.26 | x |
| 2015-09-30 | $52712.20 | $1.26 | x |
| 2015-12-31 | $76340.82 | $1.26 | x |
| 2016-09-30 | $378665.12 | $1.26 | x |
| 2017-09-30 | $271667.88 | $1.26 | x |
| 2018-12-31 | $16887.47 | $1.26 | x |
| 2019-09-30 | $-3266.92 | $1.26 | x |
| 2020-09-30 | $789.93 | $1.26 | x |
| 2021-09-30 | $2234.48 | $1.26 | x |
| 2022-09-30 | $-102.76 | $1.26 | x |
| 2023-09-30 | $-1.74 | $1.26 | x |
| 2024-09-30 | $-0.74 | $1.26 | x |
| 2025-09-30 | $2.64 | $1.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sonnet Biotherapeutics Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -149.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1611.27%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.38x
- Recent ROE (-149.36%) is below the historical average (-107.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -113.33% | -118.84% | 0.47x | 2.02x | $-885.50K |
| 2011 | -1.23% | -742.16% | 0.00x | 17.16x | $-9.25 Million |
| 2012 | -67.23% | -75.38% | 0.27x | 3.35x | $-1.27 Million |
| 2013 | -53.04% | -34.07% | 0.87x | 1.79x | $-7.09 Million |
| 2015 | -120.55% | -28.63% | 1.18x | 3.56x | $-13.14 Million |
| 2015 | -55.78% | -28.63% | 1.00x | 1.94x | $-14.31 Million |
| 2016 | -70.79% | -21.77% | 1.25x | 2.61x | $-10.36 Million |
| 2017 | -63.46% | -16.40% | 1.37x | 2.82x | $-7.87 Million |
| 2019 | 0.00% | -11.99% | 1021.63x | 0.00x | $-4.59 Million |
| 2020 | -803.50% | 0.00% | 0.00x | 2.65x | $-24.57 Million |
| 2021 | -112.34% | -5170.52% | 0.02x | 1.30x | $-27.23 Million |
| 2022 | 0.00% | -8508.34% | 0.06x | 0.00x | $-29.52 Million |
| 2023 | 0.00% | -12741.58% | 0.03x | 0.00x | $-18.81 Million |
| 2024 | 0.00% | -39929.30% | 0.01x | 0.00x | $-7.39 Million |
| 2025 | -149.36% | -1611.27% | 0.07x | 1.38x | $-17.19 Million |
Industry Comparison
This section compares Sonnet Biotherapeutics Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc (SONN) | $-3.05 Million | -113.33% | N/A | $8.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more